Silk Road Medical (NASDAQ:SILK) Given New $21.00 Price Target at JPMorgan Chase & Co.

Silk Road Medical (NASDAQ:SILK – Free Report) had its price target lifted by JPMorgan Chase & Co. from $19.00 to $21.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. Several other equities analysts also recently weighed in on SILK. Stifel Nicolaus raised […]

Related Keywords

United States ,Kevinm Klemz ,Piper Sandler ,Stifel Nicolaus ,Andrews Davis ,Company Profile ,Goldman Sachs Group Inc ,Bellevue Group ,Securities Exchange Commission ,Jpmorgan Chase Co ,Nasdaq ,Armistice Capital ,Silk Road Medical ,Free Report ,Street Capital ,Road Medical ,Get Free Report ,Exchange Commission ,Sachs Group ,Rubric Capital Management ,Neuroprotection System ,Stent System ,Peripheral Access Kit ,Dilation Catheter ,Silk Road Medical Daily ,Nasdaq Silk ,Silk ,Medical ,Boost Price Target ,